WA-TWIN-PROTOCOL
20.6.2024 09:31:27 CEST | Business Wire | Press release
Twin Protocol, a pioneer in the development of ethically engineered, personalized generative artificial intelligence (AI) technology to foster a culture of continuous knowledge sharing, announces a partnership with wellness and tech leaders, Cyberhuman.ai, and Dectec. The three companies are developing cutting-edge solutions that will democratize well-being and guide people around the world on the path of improved health and mindfulness. At the Cannes Creative Festival this week, Dr. Deepak Chopra unveils the first step in this revolutionary approach to sharing well-being knowledge across the globe – his Digital Deepak AI Twin.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620183427/en/
Celebrating innovation at Cannes Creative Festival 2024: (pictured from left to right) Bill Inman, CEO of Dectec; Stacey Engle, CEO of Twin Protocol; Deepak Chopra, MD; and Poonacha Machaiah, Co-founder of Cyberhuman.ai., announce the groundbreaking Deepak Chopra AI Twin, a collaboration at the intersection of well-being, AI, and technology. (Photo: Business Wire)
World-renowned pioneer in integrative medicine and personal transformation, Dr. Deepak Chopra previews his digital twin to further his efforts to make chronic disease optional. Digital Deepak is a groundbreaking initiative to integrate advanced technology to more effectively, securely, and personally communicate his timeless wisdom, and guide people along the path of well-being and personal growth.
Interact with Dr. Chopra’s AI Twin here: Digital Deepak. Visitors can ask him questions from a subset of his published books and will even be treated to a sneak peek of his new “Digital Dharma” book, which focuses on the core role of AI in helping individuals achieve well-being and is scheduled for publication in December. Over the coming months, Dr. Chopra’s life’s work will be made available through his digital AI twin.
The partnership between Twin Protocol, Cyberhuman.ai, and Dectec is breaking new ground in the wellness industry. Cyberhuman.ai, an AI platform for personal health and well-being, optimizes lives for peak living at home, work, play, or on the road. The platform uses advanced diagnostics and predictive analytics to provide personalized well-being program recommendations. Dectec is creating the ecosystem and digital wallet that will enable users to make purchases within the ecosystem. Twin Protocol provides the decentralized digital AI twin technology for all healthcare gurus and users, the industry’s most secure, ultra-relatable means of sharing knowledge.
Dr. Chopra’s AI Twin, born out of extensive research and development by Twin Protocol, embodies his vision for guiding individuals on a journey pursuing optimal health and vitality. His AI Twin is poised to revolutionize the future of well-being by offering a holistic approach to wellness that integrates the latest security advancements in AI and blockchain technology. Future updates to the AI Twin will add new communication capabilities and modalities.
Dr. Deepak Chopra shared his perspective on the transformative potential of the AI Twin, stating, “With digital twins and AI technology, it is becoming possible to guide more and more people around the globe on a journey of ever-improving well-being and mindfulness. Over the coming weeks and months, I will share deeper insight through my twin, safely and securely empowering individuals to leverage my assistant as a confidant, health coach, and spiritual guide.”
“The launch of Dr. Deepak Chopra’s AI Twin demonstrates the exceptional vision and capabilities of the Cyberhuman.ai, Dectec, and Twin Protocol team. This is a significant milestone in our journey towards empowering individuals to live their best, most healthy lives,” said Stacey Engle, CEO of Twin Protocol. “By combining cutting-edge technology with his profound wisdom, we are pioneering a new paradigm of well-being that is accessible, personalized, and transformative.”
A unique panel will take place this week at Cannes, exploring the transformative potential of AI and digital twins in enhancing individual well-being.
June 20, 2024
11:00 AM to 12:00 PM
Annex Beach Cannes
Boulevard de la Croisette, Cannes - France
Participants:
- Deepak Chopra – MD
- Poonacha Machaiah – Co-founder, Cyberhuman.ai
- Stacey Engle – CEO, Twin Protocol
- Bill Inman – CEO, Dectec
“AI is reinventing aspects of our world in fundamental ways, including enabling us to create a future where people around the globe can instantly harness the well-being knowledge and insights of global thought leaders such as Dr. Chopra,” said Poonacha Machaiah, co-founder of Cyberhuman.ai. “Through partnerships with world-leading tech innovators like Twin Protocol and Dectec, we are democratizing well-being and helping people live their best lives.”
“When it comes to wellness and health-related information and transactions, its essential that our data is absolutely secure,” said Bill Inman, CEO, Dectec. “With our Web3 platform and collaboration with world-class partners, we’re creating a secure ecosystem that protects users and empowers them to securely manage and improve all aspects of their well-being.”
For more information about Twin Protocol, please visit Twin Protocol.
About Cyberhuman.ai
Cyberhuman.ai is a pioneering advance in personal health and well-being. It is designed as an AI platform to help individuals optimize their lives for peak living across various environments—at home, work, play, or on the road. Leveraging a combination of advanced diagnostics and predictive analytics, the platform offers personalized well-being program recommendations.
About Dectec
Dectec is a pioneering Web3 platform that connects traditional enterprises with advanced AI and blockchain technologies. Specializing in loyalty and rewards programs, Dectec empowers businesses to expand their reach and deepen customer engagement through innovative solutions like user-friendly mobile apps, metaverse experiences, and robotics. The company’s strategy focuses on tapping into new markets with a sophisticated, user-centric wallet system, ensuring clients stay at the forefront of industry innovation for sustained success.
About Twin Protocol
The mission of Twin Protocol’s global venture is to empower individuals and organizations to create secure, dynamic digital versions of themselves to share knowledge, create legacies, and foster continuous learning. Through an advanced AI and blockchain ecosystem, Twin Protocol is revolutionizing the way knowledge and expertise are preserved, shared, and utilized. Twin Protocol, along with strategic partners including SingularityNET, is committed to helping users shape a future where knowledge is an enduring and shared asset. Learn more at Twin Protocol.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620183427/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance14.10.2026 14:00:00 CEST | Press release
Despite the remarkable progress made by ADCs, many cancer patients continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicities At World ADC 2026 San Diego, Debiopharm presented their latest ADC innovation to overcome these challenges with novel linker-payload technology, including modular dual payload linker MLINK DUO and modular cathepsin B-cleavable linker MLINK Select Research results with various MultiLINKTM Linker Technologies showcased broadening of vedotin-based ADC therapeutic index for MLINK Select ADCs, synergistic antitumor activity with MLINK Duo, and homogeneous DAR8 conjugation with MLINK HiSol Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-cli
Responsible AI for Children: IEEE Delivers a Trusted Safety Formula to Help Protect Kids Online14.10.2026 14:00:00 CEST | Press release
With children’s AI exposure surging, IEEE Standards Association certification helps ensure AI products for kids are ethically designed, independently tested and continually accountable for safety and well-beingFirst product certification issued to educational platform from Greek National Centre for Scientific Research The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, parents, educators, developers, and regulators want tools they can trust. IEEE’s Responsible AI for Children (RAIC) certification directly addresses these needs by translating global technical standards into a practical
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 202614.10.2026 14:00:00 CEST | Press release
− TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patients 16 years and older − TAK-881 may shorten infusion times and offer the opportunity for fewer required infusion sites compared to HYQVIA with 50% less volume while maintaining up to once-monthly dosing − Adult infection outcomes and safety and tolerability profiles were comparable to HYQVIA based on descriptive analyses and consistent with established IG therapy standards Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-b
Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Boardof Directors14.10.2026 13:55:00 CEST | Press release
Tirman, through his family office Abri Capital Ltd., holds 26 million DVLT shares and brings over 35 years of international investment management and corporate restructuring experience to the Company Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors. As a Datavault AI Shareholder, Mr. Tirman brings both an ownership perspective and extensive management experience to the Board. Mr. Tirman has more than 35 years of international investment management experience, focused on corporate transformation, capital strategy and value creation. He has led c
EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 13:21:00 CEST | Press release
Investment-grade, non-recourse financing will support the delivery of more than 3,000 charge points primarily across the whole of the UK along with additional development in Ireland. EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom